{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"21.7","value":"11.4"},{"groupId":"OG001","lowerLimit":"11.7","upperLimit":"32.3","value":"21.3"},{"groupId":"OG002","lowerLimit":"3.8","upperLimit":"6.1","value":"4.7"},{"groupId":"OG003","lowerLimit":"7.0","upperLimit":"10.0","value":"8.7"},{"groupId":"OG004","lowerLimit":"5.6","upperLimit":"14.9","value":"7.9"},{"groupId":"OG005","lowerLimit":"7.4","upperLimit":"10.8","value":"8.6"},{"groupId":"OG006","lowerLimit":"5.6","upperLimit":"9.5","value":"7.9"},{"groupId":"OG007","lowerLimit":"3.8","upperLimit":"5.4","value":"4.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"105"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"101"},{"groupId":"OG006","value":"102"},{"groupId":"OG007","value":"103"}],"units":"Participants"}],"description":"OS was defined as the time from the date of study treatment to the date of death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. The OS for all participants is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenvatinib (lenva) 20 mg via oral capsule once a day (QD) up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG000","title":"Cohort A: Triple Negative Breast Cancer (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG001","title":"Cohort B: Ovarian Cancer (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG002","title":"Cohort C: Gastric Cancer (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG003","title":"Cohort D1: Colorectal Cancer (Lenva + Pembro)"},{"description":"Participants received Lenva 24 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG004","title":"Cohort D2: Colorectal Cancer (Lenva)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG005","title":"Cohort E: Glioblastoma Multiforma (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG006","title":"Cohort F: Biliary Tract Cancer (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG007","title":"Cohort G: Pancreatic Cancer (Lenva + Pembro)"}],"paramType":"MEDIAN","populationDescription":"All allocated participants who received at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"Up to approximately 66 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}